கும்பல் டெங் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from கும்பல் டெங். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In கும்பல் டெங் Today - Breaking & Trending Today
Yale Cancer Center study reveals new pathway for brain tumor therapy eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Stroke-Targeting Nanoparticles Deliver Neuroprotectant to Mouse Brain Written by AZoNanoMar 12 2021 According to a new study, the delivery of NA1, a neuroprotectant, to the brain in nanoparticles decreases stroke severity and enhances survival in a mouse model of stroke. Image Credit: Alexandros A Lavdas/shutterstock.com This is a preliminary study to be presented at the American Stroke Association’s International Stroke Conference 2021. The virtual meeting will be held from March 17 th to 19 th, 2021, and is a world premiere meeting for clinicians and researchers committed to the science of stroke and brain health. In a previous human trial (the ESCAPE-NA1 trial), NA1, a small peptide that has been particularly developed to save brain cells from death following stroke, exhibited combined outcomes when NA1 was given to patients who were undergoing clot removal for severe stroke. ....
E-Mail DALLAS, March 11, 2021 When NA1, a neuroprotectant, was delivered to the brain in nanoparticles, it reduced stroke severity and improved survival in a mouse model of stroke, according to preliminary research to be presented at the American Stroke Association s International Stroke Conference 2021. The virtual meeting is March 17-19, 2021 and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health. In an earlier human trial (the ESCAPE-NA1 trial), NA1, a small peptide designed to save brain cells from death after stroke, showed mixed results when NA1 was administered to patients undergoing clot removal for severe stroke. Some patients in the trial also received the intravenous clot-busting medication tissue plasminogen activator (tPA), and these patients in particular showed a lack of improvement in functional outcomes from NA1. ....
Sherman Oaks biopharmaceutical company T-Cure Bioscience has entered into a license agreement with Chinese biotech Immunotech Biopharm Ltd. to develop a T cell therapy for renal cancer, the companies announced Wednesday. According to license agreement terms, T-Cure will receive an unspecified upfront payment from Immunotech, along with future development milestone payments and tiered royalties on net sales of the treatment. T-Cure’s renal cancer immunotherapy product, referred to as 800TCR, is in Phase 1 clinical trials. “With its advanced research, manufacturing, clinical operations and marketing, Immunotech represents an ideal partner to help us advance the 800TCR in China,” Dr. Gang Teng, chief executive of T-Cure, said in a statement. ....